These findings suggest several pathways to elucidate the role of endocan in metabolic syndrome, particularly suggesting that quantitative evaluation of MetS severity could be more effective in precisely forecasting the risk of endothelial dysfunction and cardiovascular disease. This evidence concerns the gene ESM1 and metabolic syndrome.